Acorda Therapeutics Inc Stock Ownership - Who owns Acorda Therapeutics?

Insider buying vs selling

Have Acorda Therapeutics Inc insiders been buying or selling?
Ron CohenPresident and CEO2023-03-1710,000$0.65
Ron CohenPresident and CEO2023-03-1610,156$0.60
Kerry M. ClemChief Commercial Officer2022-09-031,511$0.40
Lauren M. SabellaChief Operating Officer2022-09-031,511$0.40

1 of 1

ACOR insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ACOR insiders and whales buy or sell their stock.

ACOR Shareholders

What type of owners hold Acorda Therapeutics Inc stock?
Scopia Capital Management LP19.52%4,750,219$2.38MInsider
Ridgeback Capital Investments Ltd10.80%2,628,762$1.32MInsider
Michael Steinmetz7.42%1,806,800$907.01kInsider
Davidson Kempner Partners7.41%1,803,070$905.14kInstitution
Davidson Kempner Capital Management LP7.41%1,803,070$905.14kInstitution
Sandra Phd Panem6.74%1,640,525$823.54kInsider
Standish Fleming4.10%998,889$501.44kInsider
Renaissance Technologies LLC3.64%885,292$444.42kInstitution
John H. Friedman3.59%873,364$438.43kInsider
Acadian Asset Management LLC2.80%682,638$342.68kInstitution

1 of 3

ACOR vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ACOR31.68%68.32%Net BuyingNet Buying
MNPR1.15%98.85%Net SellingNet Selling
IBIO4.58%95.42%Net SellingNet Selling
BWV10.19%26.79%Net Selling

Acorda Therapeutics Stock Ownership FAQ

Who owns Acorda Therapeutics?

Acorda Therapeutics (NASDAQ: ACOR) is owned by 534.36% institutional shareholders, 1,152.49% Acorda Therapeutics insiders, and 0.00% retail investors. Scopia Capital Management LP is the largest individual Acorda Therapeutics shareholder, owning 4.75M shares representing 390.36% of the company. Scopia Capital Management LP's Acorda Therapeutics shares are currently valued at $48.55M.

If you're new to stock investing, here's how to buy Acorda Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.